January 12, 2011 – U.S. healthcare spending experienced historically low rates of growth in 2009 and 2010 according to the annual report of national health expenditures (NHE) published in the January issue of the journal Health Affairs. 

January 12, 2012 — An article in the January issue of the Journal of the American College of Radiology summarizes methods for radiation dose optimization in pediatric computed tomography (CT) scans.

January 11, 2012 — HeartWare International, Inc. and Dualis MedTech GmbH, a subsidiary of AVRA Surgical, Inc., announced an agreement to develop ventricular assist devices with wireless, transcutaneous energy transfer system (TETS) technology exclusively for HeartWare.

January 11, 2012 – Siemens Healthcare has announced that the version 2.0 of the Acuson SC2000 volume imaging ultrasound system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

January 9, 2012 – Janssen Research and Development, LLC (JRD) announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular events in patients with acute coronary syndrome (ACS).

January 9, 2012 - Uninsured patients, and those with Medicaid, receive far less imaging services than those with private insurance during emergency department (ED) visits, according to a study in the January issue of the Journal of the American College of Radiology.

January 9, 2012 - GE Healthcare announced the Brivo NM615 has received clearance from the U.S. Food and Drug Administration (FDA). 

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower rates of restenosis, stent thrombosis and mortality than older DES and bare-metal stents.

January 6, 2012 - C. R. Bard recently announced it acquired drug-eluting balloon maker Lutonix Inc. for $225 million. Following successful approval of a U.S. Food and Drug Administration (FDA) pre-market approval (PMA), an additional $100 million will be paid.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now